---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-25-000025"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:11:33.024512+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Travere Q1 net product sales $75.9M; FILSPARI sales $55.9M, net loss narrows to $0.47/share

## Summary
- Net product sales $75.9M (1Q25) vs $40.0M (1Q24), driven by FILSPARI launch.
- FILSPARI U.S. net sales $55.9M; 703 new patient start forms in quarter.
- Net loss $41.2M ($0.47/share) vs $136.1M ($1.76/share) YoY; adj. net loss $16.9M.
- Cash & securities $322.2M; sNDA submitted for full approval of FILSPARI in FSGS.
- EU and UK converted FILSPARI to full approval in IgAN; $17.5M milestone from CSL Vifor expected Q2.

## SEC filing metadata
- accession: 0001438533-25-000025
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000025/0001438533-25-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000025/tvtx-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-25-000025
- JSON: https://secwatch.observer/filing/0001438533-25-000025.json
- Plain text: https://secwatch.observer/filing/0001438533-25-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.